MedTrace Logo

Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects

NCT04607512 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-03-09

No results posted yet for this study

Summary

This study is designed to evaluate the effects of telaglenastat on cardiac repolarization (relative to placebo) in healthy adult subjects.

Conditions

  • Cardiac Safety

Interventions

DRUG

telaglenastat

glutaminase inhibitor

OTHER

telaglenastat placebo

matching placebo for telaglenastat

OTHER

moxifloxicin

positive control

Sponsors & Collaborators

  • Calithera Biosciences, Inc

    lead INDUSTRY

Principal Investigators

  • Sunu Valasseri, MD · Celerion

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-05
Primary Completion
2020-12-30
Completion
2020-12-30
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04607512 on ClinicalTrials.gov